Cempra To Present Late-Breaker On Solithromycin Reducing Inflammation In An Animal Model For Cancer Chemotherapy-Induced Lung Injury
3/27/2014 9:57:17 AM
CHAPEL HILL, N.C., March 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin reduced inflammation in an animal model for inflammatory lung disease at the American Thoracic Society (ATS) 2014 International Conference in San Diego.
Help employers find you! Check out all the jobs and post your resume.
comments powered by